US00847G8042 - Common Stock
AGENUS INC
NASDAQ:AGEN (5/8/2024, 7:00:00 PM)
After market: 11.55 +0.08 (+0.7%)11.47
-0.54 (-4.5%)
Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 533 full-time employees. The company went IPO on 2000-02-04. The firm is focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company’s I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy and vaccine adjuvants. The Company’s antibody candidates are botensilimab (a CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody). Botensilimab is in three Phase 2 studies as a monotherapy (melanoma), in combination with chemotherapy (pancreatic cancer), and in combination with balstilimab (microsatellite stable colorectal cancer (MSS CRC)). Its clinical-stage portfolio also includes Botensilimab (AGEN1181), Balstilimab (AGEN2034), Zalifrelimab (AGEN1884), AGEN2373, AGEN1423, AGEN1571, MK-4830, INCAGN1876, INCAGN2390, INCAGN2385, BMS-986442, UGN-301, agenT-797 and QS-21 STIMULON. AGEN2373, a CD137 monospecific antibody in a Phase 1b clinical trial.
AGENUS INC
3 Forbes Rd
Lexington MASSACHUSETTS 02421
P: 17816744400
CEO: Garo H. Armen
Employees: 533
Website: https://agenusbio.com/
AGEN earnings call for the period ending March 31, 2024.
AGEN stock results show that Agenus missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
This small-cap biotech stock is surging. Time to buy?
Here you can normally see the latest stock twits on AGEN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: